Viz.ai to Present Expanded Data on ALADIN and New Data on ADVANCE Expanding Its Stroke Pipeline at the 2018 ESOC

Viz.ai to Present Expanded Data on ALADIN and New Data on ADVANCE Expanding Its Stroke Pipeline at the 2018 ESOC

Viz.ai, Inc., an applied artificial intelligence healthcare company, announced today that new data on its approved and investigational technologies for acute ischemic and hemorrhagic stroke will be presented during the 4th European Stroke Organization Conference (ESOC) from May 16-18 in Gothenburg, Sweden.

Viz.ai Receives FDA Clearance for Automated Computed Tomography Perfusion (CTP) Software

Viz.ai Receives FDA Clearance for Automated Computed Tomography Perfusion (CTP) Software

Viz.ai, Inc., an applied artificial intelligence healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has cleared Viz CTP through the 510(k) pathway. Viz CTP offers image processing software to view and analyze functional and dynamic CT perfusion images. This clearance offers healthcare providers another important tool for automated cerebral-image analysis.

Viz.ai Granted De Novo FDA Clearance for First Artificial Intelligence Triage Software

 Viz.ai Granted De Novo FDA Clearance for First Artificial Intelligence Triage Software

Viz.ai, Inc., an applied artificial intelligence healthcare company announced that the U.S. Food and Drug Administration (FDA) has granted a De Novo request for the first-ever Computer-Aided Triage and Notification Platform to identify Large Vessel Occlusion (LVO) strokes in CTA imaging. This regulatory clearance compliments Viz.ai's recent European CE Mark for the product in January 2018.

Viz.ai Hires World-Renowned Stroke Executive as Chief Commercial Officer

Viz.ai Hires World-Renowned Stroke Executive as Chief Commercial Officer

Viz.ai, a revolutionary Direct-to-Intervention healthcare company, today announced that Conrad Yiu has been named as its Chief Commercial Officer (CCO). As CCO, Yiu has responsibility for all customer-facing activities, including global sales, marketing, product development, clinical research, business development, and customer support. Yiu will report directly to Chris Mansi, M.D., Viz.ai’s President and CEO.

Viz.ai Announces CE Mark for the First AI Powered Direct-to-Intervention System

Viz.ai Announces CE Mark for the First AI Powered Direct-to-Intervention System

Viz.ai, a leader in artificial intelligence imaging and workflow software, today announced the CE (Conformité Européenne) Mark of its Direct-to-Intervention system, ContaCT, a novel approach to stroke care that automatically analyzes brain CTs and notifies a specialist that a suspected large vessel occlusion has been identified.